Technology

BioSite, Which Has Partnered with Samsung Bioepis, Also Receives Interest from Japanese Big Pharma

NA EUN-KYUNG
2026-11-23 07:31:02
[Edaily Reporter NA EUN-KYUNG ] Astellas Pharma, a major Japanese pharmaceutical company, has also expressed interest in the new drug development technology from BioSite that Samsung Bioepis had previously highlighted. BioSite, a new drug development company specializing in AI-powered chemoproteomics technology, plans to optimize candidate compounds using its proprietary “Javelin” platform and secure rights to the results of future joint development with Astellas, paving the way for subsequent technology export negotiations.

Yang Hee-jung and Yoo Ho-jin, co-CEOs of BioSite, stated in a recent interview with E-Daily at the company’s office in Seongsu-dong, Seongdong-gu, Seoul, “Through the agreement that took effect this month, we will conduct joint development research with Astellas Pharma to optimize lead compounds and secure preclinical data.” At BioSite, CEO Yang oversees experimental research and management, while CEO Yoo, serving as Chief Technology Officer (CTO), leads AI-based analytical research.

BioSite Co-CEOs Yang Hee-jung (left) and Yoo Ho-jin (right) (Photo: E-Daily, Reporter NA EUN-KYUNG )

Japan Made the Initial Proposal… Equal Partnership for Future Technology Exports
This collaboration began when Astellas first approached BioSite in the second half of last year. Specific discussions took place during a meeting in late December of last year, and the agreement was recently finalized following a review of technology and data, selection for a government-funded project, and contract negotiations.

Astellas decided to develop a first-in-class innovative drug for a different indication by utilizing a target related to autoimmune diseases that it had been researching. According to the company, discussions took shape after Astellas reviewed the data based on BioSite’s technology and experimental capabilities and determined that it would be possible to develop a new drug even for targets that had not previously been used for that indication.

CEO Yang stated, “Based on the data we presented, Astellas analyzed market potential and other factors to determine whether it would be possible to develop treatments for other indications using that target. We supported this analysis with our data, and ultimately, the direction for joint development was finalized.”

BioSite will lead this joint research. The company will oversee target validation using Javelin, AI-based molecular design, and lead compound optimization, while also conducting cell and animal experiments. Astellas will provide its proprietary data and expertise, offer guidance on the development direction, and support the research.

BioSite will receive 2.5 billion won in research funding over a maximum of five years through the Global Cooperation R&D Program administered by the Korea Institute for Advancement of Technology (KIAT). In the first phase, a total of 1.5 billion won—500 million won per year for three years—will be disbursed. This is government funding for joint development, not a technology transfer upfront payment from Astellas.

CEO Yang added, “Although this is structured as a government project, the actual contract was signed on a company-to-company basis.”

Subsequently, both companies will equally secure intellectual property (IP) rights for the results of the joint development. Astellas holds the right of first refusal and can negotiate a follow-up technology transfer agreement—including an upfront payment and milestone payments—based on the development data. This structure allows BioSite to negotiate as a partner with rights to the results, rather than merely providing analytical services.

The Phase 1 objective is to develop a lead compound that addresses the weaknesses of the drug Astellas was already developing and to secure basic pharmacokinetic (PK) data from cellular and animal studies. Additional preclinical studies will follow; however, if the results are promising, negotiations for technology transfer may begin immediately upon completion of Phase 1.

CEO Yang elaborated, “If the weaknesses of the compound previously under development are addressed and it is confirmed to have excellent efficacy, and if the results from the Phase 1 animal studies show outstanding efficacy and a high probability of success, we will terminate the animal studies during the efficacy evaluation phase and immediately enter into a formal technology transfer agreement with Astellas.”
Collaboration with Bioepis on New Antigen Discovery… Pursuing Monetization Through Technology Export
Joint development
with
Samsung Bioepis, BioSite’s first major partner, is also proceeding smoothly. Since being selected last July for the open innovation program run by Seoul BioHub and Samsung Bioepis, BioSite has been focusing on the discovery of new antigens and early-stage development.

CEO Yang explained, “The collaboration with Samsung Bioepis is structured so that we will produce results over approximately one year and undergo an evaluation around August of next year to determine whether a follow-up agreement will be signed,” adding, “We will verify whether a candidate has value as a new antigen, from discovery through basic early-stage development.”

Javelin, which has attracted the attention of partner companies, is a drug target analysis platform that combines chemoproteomics with AI. Using mass spectrometry, it analyzes interactions with more than 7,000 proteins at once and identifies binding sites without chemically modifying the drug. It confirms not only whether the drug acts on other proteins in addition to its intended target but also exactly which part of the protein it binds to, providing clues for optimizing candidate compounds.

CEO Yoo stated, “Javelin’s greatest strength is that it can be applied to a wide range of drugs—from small molecules to antibodies—on a single platform,” adding, “It allows us to directly examine which parts of a drug need to be optimized.”

The company explains that using Javelin reduces the synthesis and experimentation required for drug optimization, thereby shortening the development timeline. In small-molecule drug development, the conventional optimization process often involves synthesizing hundreds of compounds and repeating experiments while modifying their structures. In contrast, BioSite used Javelin in its own projects to identify key interaction sites, thereby narrowing down the scope of synthesis.

CEO Yang said, “By using Javelin, we shortened the optimization of our in-house compounds by more than several months and synthesized only a few dozen compounds,” adding, “We were able to identify key interaction sites using the platform and demonstrate to potential partners that the compounds actually functioned when those sites were modified.”

CEO Yang interprets that this efficiency is precisely why a Japanese pharmaceutical company with strengths in organic chemistry and drug synthesis approached BioSite. CEO Yang explained that Astellas had already researched the structures of numerous drugs, noting, “By examining the actual binding relationships between drugs and proteins, we can modify structures based on existing information more quickly.” He added, “I believe this is why Astellas determined that we are a company capable of collaborating on drug design.”

The scope of proteomics applications is also expanding in the global market. In 2024, Japan’s Otsuka Pharmaceutical acquired U.S.-based Zanata Therapeutics, which owns a chemical proteomics platform, for up to $1.125 billion (approximately 1.5 trillion won), including an upfront payment of $800 million (approximately 1 trillion won). CEO Yoo said, “As mass spectrometry equipment has become more sophisticated recently, the range of research that can be conducted has expanded,” adding, “Chemical proteomics is just one part of that, and there are still many areas left to explore.”

He explained that the reason partner companies are showing interest even in the absence of clinical-stage drugs utilizing Javelin is the demand for new targets and novel approaches to drug development. CEO Yang noted that in the global market, technology deals are made even in the early stages once the potential of a new target or a first-in-class drug is confirmed, and he stated that BioSite also aims to achieve this.

The company’s business strategy extends beyond simply providing analytical services for a fee. It places emphasis on securing proprietary assets through its platform and securing rights to the results via joint development. The primary goal is to secure a meaningful technology export agreement by next year. If this is achieved, the company expects to reach the break-even point (BEP) around 2028.

The company recently completed the subscription of 15.8 billion won in Series B funding, and additional investment is currently underway. The two co-CEOs are the largest shareholders, while the major financial investors (FIs) include SV Investment, DSC Investment, and Schmidt. New participants in this round included Soliderus Investment, IBK Capital, S&S Investment, IBK Industrial Bank of Korea, Quad Asset Management, BSK Investment, HLB Investment, and Aju IB Investment. The company plans to allocate the funds toward expanding its research team and mass spectrometry equipment, synthesizing and optimizing its proprietary candidate compounds, and covering joint development costs.

The company plans to elevate its collaborations with Astellas and Samsung Bioepis to technology export agreements before proceeding with its initial public offering (IPO). CEO Yoo stated, “We are not currently considering a Series C funding round,” adding, “Once decisions on other projects are finalized to some extent in early 2029, we intend to apply for a technology evaluation without additional investment and aim for a technology-based special listing on KOSDAQ that same year.”

Economy

Corporation

IT·Science

Economy

"Chinese Stablecoin Payments Surge After U.S. AI Model Launch"... Appears to Circumvent Export Restrictions

It has been revealed that stablecoin transactions originating from cryptocurrency wallets linked to China surged immediately after the release of a major U.S. artificial intelligence (AI) model. Analy…
2026-11-23 07:28:14

Corporation

"Beyond the Domestic Home Shopping Market to Vietnam": GS Retail Sees Success in Export Consultations with Small and Medium-Sized Enterprises

GS Retail(007070)has supported domestic small and medium-sized partner companies in Vietnam in expanding their overseas sales channels, resulting in export consultation deals totaling approximately $1…
2026-11-22 18:23:06

IT·Science

BioSite, Which Has Partnered with Samsung Bioepis, Also Receives Interest from Japanese Big Pharma

Astellas Pharma, a major Japanese pharmaceutical company, has also expressed interest in the new drug development technology from BioSite that Samsung Bioepis had previously highlighted. BioSite, a ne…
2026-11-23 07:31:02